Monopar Therapeutics (MNPR) Free Cash Flow (2017 - 2020)

Monopar Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$1.2 million for Q4 2020.

  • For Q4 2020, Free Cash Flow fell 85.54% year-over-year to -$1.2 million; the TTM value through Dec 2020 reached -$4.7 million, down 54.5%, while the annual FY2024 figure was -$6.4 million, 18.5% up from the prior year.
  • Free Cash Flow for Q4 2020 was -$1.2 million at Monopar Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$305128.0 in Q2 2017 and bottomed at -$1.3 million in Q3 2020.
  • The 4-year median for Free Cash Flow is -$780856.0 (2018), against an average of -$811744.3.
  • The largest YoY upside for Free Cash Flow was 49.82% in 2018 against a maximum downside of 159.67% in 2018.
  • A 4-year view of Free Cash Flow shows it stood at -$816021.0 in 2017, then surged by 36.37% to -$519212.0 in 2018, then decreased by 28.79% to -$668705.0 in 2019, then crashed by 85.54% to -$1.2 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Free Cash Flow are -$1.2 million (Q4 2020), -$1.3 million (Q3 2020), and -$995474.0 (Q2 2020).